Trevi Therapeutics Inc (TRVI) — Cash Flow-to-Debt Ratio
Trevi Therapeutics Inc (TRVI) has a Cash Flow-to-Debt Ratio of -1.14x as of September 2025, meaning its operating cash flow of $-10.88 Million could theoretically repay -1% of its total liabilities ($9.57 Million) in one year. See how liquid is Trevi Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Trevi Therapeutics Inc Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Trevi Therapeutics Inc across 9 annual periods. Also explore TRVI shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Trevi Therapeutics Inc (2016–2024)
Year-by-year debt coverage analysis for Trevi Therapeutics Inc. For market capitalisation and broader financial context, see TRVI stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.40x | $-38.26 Million | $11.26 Million | ▲ +26.5% |
| 2023 | -4.63x | $-31.71 Million | $6.86 Million | ▼ -155.4% |
| 2022 | -1.81x | $-28.18 Million | $15.56 Million | ▼ -33.9% |
| 2021 | -1.35x | $-28.95 Million | $21.40 Million | ▲ +7.4% |
| 2020 | -1.46x | $-29.00 Million | $19.85 Million | ▲ +65.5% |
| 2019 | -4.23x | $-23.09 Million | $5.46 Million | ▲ +26.4% |
| 2018 | -5.75x | $-18.29 Million | $3.18 Million | ▼ -437.0% |
| 2017 | -1.07x | $-7.97 Million | $7.45 Million | ▼ -146.9% |
| 2016 | -0.43x | $-11.19 Million | $25.82 Million | — |